Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellistem-OA in knee osteoarthritis
NCT03810521Phase 1Unknown
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CELLISTEM-OA in knee osteoarthritis (OA) (3 arms). Primary endpoint: Incidence of adverse events at 6 months. Status: unknown.
02
Drugs
CELLISTEM-OA
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03810521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810521.